Literature DB >> 9311894

Influence of membrane anchoring and cytoplasmic domains on the fusogenic activity of vesicular stomatitis virus glycoprotein G.

D Odell1, E Wanas, J Yan, H P Ghosh.   

Abstract

Chimeric proteins in which the transmembrane anchoring sequence (TM) or both the TM and the cytoplasmic tail (CT) of vesicular stomatitis virus glycoprotein G were replaced with corresponding domains of viral or cellular integral membrane proteins were used to examine the influence of these domains on acidic-pH-induced membrane fusion by G protein. The TM and CT of G were also replaced with the lipid anchor glycosylphosphatidylinositol. Hybrids containing foreign TM or TM and CT sequences were fusogenic at acidic pH but glycosylphosphatidylinositol-anchored G was nonfusogenic at acidic pH. The results suggest that the fusogenic activity of G protein requires membrane anchoring by a hydrophobic peptide sequence and the specific amino acid sequence of the TM has no influence on fusogenic activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311894      PMCID: PMC192161          DOI: 10.1128/JVI.71.10.7996-8000.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

Review 2.  Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism.

Authors:  Y Gaudin; R W Ruigrok; J Brunner
Journal:  J Gen Virol       Date:  1995-07       Impact factor: 3.891

3.  Signal for attachment of a phospholipid membrane anchor in decay accelerating factor.

Authors:  I W Caras; G N Weddell; M A Davitz; V Nussenzweig; D W Martin
Journal:  Science       Date:  1987-11-27       Impact factor: 47.728

4.  A cell line expressing vesicular stomatitis virus glycoprotein fuses at low pH.

Authors:  R Z Florkiewicz; J K Rose
Journal:  Science       Date:  1984-08-17       Impact factor: 47.728

Review 5.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.

Authors:  D C Wiley; J J Skehel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

6.  Nucleotide sequences of the mRNA's encoding the vesicular stomatitis virus G and M proteins determined from cDNA clones containing the complete coding regions.

Authors:  J K Rose; C J Gallione
Journal:  J Virol       Date:  1981-08       Impact factor: 5.103

7.  Nucleotide sequence specifying the glycoprotein gene, gB, of herpes simplex virus type 1.

Authors:  D J Bzik; B A Fox; N A DeLuca; S Person
Journal:  Virology       Date:  1984-03       Impact factor: 3.616

8.  Haemagglutinin of influenza virus expressed from a cloned gene promotes membrane fusion.

Authors:  J White; A Helenius; M J Gething
Journal:  Nature       Date:  1982-12-16       Impact factor: 49.962

9.  Differential effects of mutations in three domains on folding, quaternary structure, and intracellular transport of vesicular stomatitis virus G protein.

Authors:  R W Doms; A Ruusala; C Machamer; J Helenius; A Helenius; J K Rose
Journal:  J Cell Biol       Date:  1988-07       Impact factor: 10.539

10.  Cell surface expression of fusogenic vesicular stomatitis virus G protein from cloned cDNA.

Authors:  H Riedel; C Kondor-Koch; H Garoff
Journal:  EMBO J       Date:  1984-07       Impact factor: 11.598

View more
  45 in total

1.  The role of the membrane-spanning domain sequence in glycoprotein-mediated membrane fusion.

Authors:  G M Taylor; D A Sanders
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

2.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Modification of the cytoplasmic domain of influenza virus hemagglutinin affects enlargement of the fusion pore.

Authors:  C Kozerski; E Ponimaskin; B Schroth-Diez; M F Schmidt; A Herrmann
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion.

Authors:  G B Melikyan; S Lin; M G Roth; F S Cohen
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

5.  The transmembrane domain sequence affects the structure and function of the Newcastle disease virus fusion protein.

Authors:  Kathryn A Gravel; Lori W McGinnes; Julie Reitter; Trudy G Morrison
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

6.  The transmembrane domain and cytoplasmic tail of herpes simplex virus type 1 glycoprotein H play a role in membrane fusion.

Authors:  Andrew Harman; Helena Browne; Tony Minson
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 7.  The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement.

Authors:  F S Cohen; G B Melikyan
Journal:  J Membr Biol       Date:  2004-05-01       Impact factor: 1.843

8.  The paramyxovirus fusion protein C-terminal region: mutagenesis indicates an indivisible protein unit.

Authors:  Aarohi Zokarkar; Robert A Lamb
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

9.  Reovirus FAST protein transmembrane domains function in a modular, primary sequence-independent manner to mediate cell-cell membrane fusion.

Authors:  Eileen K Clancy; Roy Duncan
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

10.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.